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Background: Porcine circovirus type-2b (PCV2b) is recognized as the etiological agent of the various clinical
manifestations of porcine circovirus-associated disease (PCVAD). Previous studies have demonstrated effectiveness
of chimeric PCV1-2 vaccines against PCV2b challenge. In this study, the efficacy of inactivated and live-attenuated
(2 × 103.5 or 2 × 104.0 50 % tissue culture infective dose [TCID50] dose) chimeric PCV1-2b vaccines was compared
side-by-side in conventional pigs.
Methods: Twenty-seven non-PCV2 viremic pigs without PCV2-specific antibody were randomly divided into six
groups, including four vaccinated and challenged groups, a nonvaccinated challenged group, and a mock group.
All pigs except those in the mock group were challenged at 28 days post vaccination (DPV) using PCV2b.
Results: Both inactivated and live-attenuated chimeric PCV1-2b vaccines induced a robust antibody responses,
and significantly decreased microscopic lesion and lower viral loads in serum or superficial inguinal lymph nodes
(SILN) compared with that in the nonvaccinated challenged group. PCV2 antibody titers decreased after 7 days
post challenge (DPC) in pigs administered the inactivated PCV1-2b vaccine and they were lower than those in
pigs inoculated with live-attenuated PCV1-2b on the day of necropsy. Moreover, no viremia was present in pigs
inoculated with live-attenuated PCV1-2b vaccine at 21 DPC regardless of the dose difference.
Conclusions: The results demonstrated that both inactivated and live-attenuated chimeric PCV1-2b vaccines were
effective to induce protective immunity against PCV2b infection.
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Porcine circovirus type 2 (PCV2) is the primary causative
agent of the postweaning multisystemic wasting syndrome
(PMWS). This disease was first identified and reported in
western Canada in 1991 [1, 2]. Along with PMWS, PCV2
is also associated with a number of diseases and syn-
dromes collectively called porcine circovirus-associated
disease (PCVAD) [3–5]. PMWS is recognized as one of
the most economically important diseases in the global
swine industry.
Porcine circovirus (PCV) is a small, nonenveloped virus
with a single-strand circular DNA genome of 1.7 kb in the
family Circoviridae [6]. Two genotypes of PCV have been
identified, PCV type 1 (PCV1) and PCV type 2 (PCV2). In
general, it is known that PCV1 is nonpathogenic, however,
PCV1 can produce pathology in the lungs of porcine fe-
tuses [7]. Whereas the virus isolated from pig with PMWS
has been designated PCV2 [1, 8]. PCV2 genome has
three major open reading frames (ORFs). ORF1 encodes
viral replication-associated proteins [9, 10], ORF2 encodes
the viral immunogenic protein, which has been the target
for developing the recombinant vaccines [6, 11], ORF3
encodes an apoptosis associated protein that plays im-
portant roles in the pathogenesis of PCV2 [12]. Cur-
rently, PCV2 can be further divided into three main
subtypes: PCV2a, which is further subdivided into five
clusters, 2A to 2E; PCV2b, which is subdivided into
three clusters, 1A to 1C [13, 14]; and PCV2c, which
has only been reported in Denmark [15]. PCV2a and
PCV2b have both been associated with clinical PCVAD
of varying degrees of severity [16, 17]. PCV2b has been
suggested as being potentially more pathogenic than
PCV2a [18, 19].
It has been shown that vaccinations are a major tool
for reducing PCVAD losses in swine populations. There
are currently several types of commercial vaccine prod-
ucts available worldwide and they differ in antigen. One
vaccine is based on the inactivated PCV2a virus [6]. Two
subunit vaccines are based on capsid protein expressed
in the baculovirus system. The other chimeric PCV1-2a
vaccine contains the genomic backbone of PCV1 with
the capsid gene replaced by that of PCV2a [20, 21].Table 1 Grouping and treatment of experimental pigs
Group Vaccine Vaccine dose (TCID50)
1 Live-attenuated PCV1-2b 2 × 103.5
2 Live-attenuated PCV1-2b 2 × 104.0
3 Inactivated PCV1-2b vaccine 2 × 105.0
4a Inactivated PCV2b vaccine X 2 ml
5 Challenge without vaccination -
6 Mock group -
aOne pig died after routine bleeding at 7 DPV due to massive hemorrhagingSeveral published articles revealed that these inactivated
vaccines were effective in inducing neutralizing anti-
bodies and in reducing PCV2 viremia [22–24]. More-
over, it has been reported that pigs vaccinated with 103.5
or 104.0 50 % tissue culture infective dose (TCID50)/ml
dose live-attenuated chimeric PCV1-2 vaccine developed
high levels of antibody and the vaccinated pigs were
fully protected against challenge with PCV2 [24–27].
However, there has been less side-by-side comparison
between the efficacy of experimental inactivated and
live-attenuated PCV1-2b vaccines and the live-attenuated
vaccines with different doses (2 × 103.5 or 2 × 104.0 TCID50
dose) in growing pigs. In this study we demonstrated
that pigs can be effectively protected against PCV2b




Clinical signs and pathological lesions were not found in
the vaccinated and mock groups, whereas two pigs in
the challenged group were markedly depressed and had
fever symptoms for 1 day (40.2 °C-41.4 °C). One pig in
the inactivated PCV2b vaccine group died after routine
blood collection on 7 days post vaccination (DPV) be-
cause of massive hemorrhages in the neck area. The
average daily weight gain (ADWG) ranged from 0.30
to 0.40 kg/day during the growing period (3–7 weeks
of age), with no significant differences among groups.
The ADWG ranged from 0.51 to 0.69 kg/DPC (7–10
weeks of age), with no significant differences among
groups (Table 2).
Anti-PCV2 IgG antibodies
No PCV2-specific antibodies were detected in all five
groups at the time of vaccination, and PCV2-specific
antibodies were not detected in the mock group through-
out the experiment. Seroconversion to PCV2-specific anti-
bodies was first detected at 14 DPV in vaccinated pigs (the
IFA antibody titers ranged from 1:10 to 1:400), and all five
pigs in the vaccinated groups were seropositive against
PCV2 by 21 DPV (the IFA antibody titers ranged fromVaccination day Challenge dose (TCID50) Challenge day
21 2 × 104.8 49
21 2 × 104.8 49
21 2 × 104.8 49
21 2 × 104.8 49
- 2 × 104.8 49
- - -
Table 2 Fever and ADWG from challenge day (28 DPV) to necropsy day (21 DPC)
Group Days with fever
(≥40 °C)
Body weight ADWG before
challenge
ADWG after
challengeDay at vaccination Day at challenge 28 DPC
1 0 9.54 ± 0.34 20.84 ± 0.63 35.38 ± 1.06 0.40 ± 0.01 0.69 ± 0.03
2 0 9.58 ± 0.81 20.02 ± 1.79 32.16 ± 4.03 0.37 ± 0.04 0.58 ± 0.11
3 0 6.58 ± 0.26 16.48 ± 0.95 27.18 ± 1.94 0.35 ± 0.03 0.51 ± 0.05
4 0 6.85 ± 0.38 18.15 ± 1.21 30.30 ± 1.87 0.40 ± 0.03 0.58 ± 0.03
5 0.40 ± 0.25 7.10 ± 0.50 15.40 ± 1.12 26.88 ± 2.08 0.30 ± 0.04 0.55 ± 0.05
6 0 6.55 ± 0.25 16.15 ± 1.35 31.10 ± 2.80 0.34 ± 0.04 0.61 ± 0.07
ADWG average daily weight gain, DPC days post challenge, DPV days post vaccination
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2 × 104.0 TCID50 dose live-attenuated vaccine had higher
and earlier PCV2 antibodies. On 14 DPV, 80 % (4 out of
5) of the pigs in the inactivated and 2 × 104.0 TCID50 dose
live-attenuated vaccine groups were seropositive, the IFA
antibody titers were 0, 1:10, 1:10, 1:100, and 1:400 and 0,
1:10, 1:10, 1:10, and 1:400, respectively, whereas only 40 %
(2 out of 5) of the pigs vaccinated with 2 × 103.5 TCID50
dose live-attenuated vaccine had seroconversion to PCV2;
the IFA antibody titers were 0, 0, 0, 1:10, and 1: 400. The
IFA antibody titers peaked at 35 DPV or 42 DPV and
remained high on the day of necropsy in the pigs vacci-
nated with the 2 × 104.0 TCID50 dose and the 2 × 10
3.5
TCID50 dose; however, PCV2 antibody titers decreased
from 35 DPV in pigs vaccinated with inactivated PCV1-2b.
Regarding commercial inactivated PCV2b vaccine X, the
PCV2 antibody levels were highest at 28 DPV (the
mean IFA antibody titer was 1:5600) and then declined
rapidly at 35 DPV. For the nonvaccinated challenged
group, all five pigs seroconverted to PCV2-specific
antibodies at 14 DPC (the IFA antibody titers ranged
from 1:400 to 1:1600). There were no significant differ-
ences in the mean PCV2-specific antibodies between any
of the vaccinated groups (Fig. 1).Fig. 1 Dynamics of mean values of IFA antibody titers in each
group. The grouping and treatment of the experimental pigs are
summarized in Table 1Neutralizing antibodies
On the day of vaccination, no NA antibodies were de-
tected among all five groups. Remarkable amounts of
NA were detected in the vaccinated pigs at 14 DPV,
and the NA titers in pigs vaccinated with inactivated
PCV1-2b were higher than those in pigs vaccinated with
the live-attenuated vaccine; the NA titers were 4.8 ± 0.80,
4.8 ± 0.80, 5.6 ± 0.98, and 5.0 ± 1.00 in groups 1, 2, 3, and 4,
respectively. NA titers increased significantly on the day of
challenge (28 DPV) when they were 25.60 ± 3.92, 28.80 ±
3.20, 28.80 ± 3.20, and 20.0 ± 4.00, respectively. In general,
the inactivated and 2 × 104.0 TCID50 dose live-attenuated
vaccines induced a higher level of NA titers than 2 × 103.5
TCID50 dose live-attenuated and commercial inactivated
PCV2b vaccines during the course of the study, which cor-
responded to the PCV2 IFA antibody titers. The NA titers
were not detected in pigs in the mock group throughout
the experiment (Fig. 2).Detection of PCV2 DNA in serum
PCV2 DNA was not detected in any pigs before chal-
lenge or in pigs in the mock group at any sampling time
point. The loads of PCV2 DNA amounts per milliliter of
serum are summarized in Table 3.Fig. 2 Mean values of the serum neutralizing antibody (NA) titers in
the different groups. The grouping and treatment of the experimental
pigs are summarized in Table 1
Table 3 Prevalence and group mean log10 of PCV2 genomic copies/ml serum in pigs at different DPC
Group 7 DPC (mean log10 of PCV2 copies) 14 DPC (mean log10 of PCV2 copies) 21 DPC (mean log10 of PCV2 copies)
1 1/5 (1.56) 2/5 (3.01) 0/5 (0.00)
2 0/5 (0.00) 1/5 (1.33) 0/5 (0.00)
3 0/5 (0.00) 0/5 (0.00) 1/5 (1.11)
4 1/4 (1.74) 1/4 (1.61) 1/4 (1.42)
5 5/5 (7.39) 5/5 (8.22) 5/5 (7.37)
6 0/2 (0.00) 0/2 (0.00) 0/2 (0.00)
DPC days post challenge, DPV days post vaccination
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vaccine group, PCV2 virus DNA was detected in one of
five pigs with a load of 101.56 PCV2 genomic copy num-
bers at 7 DPC. At 14 DPC, two of five pigs were found to
have approximately 103.01 PCV2 genomic copy numbers,
and no PCV2 genomic copy numbers were detected in
any of five pigs at 21 DPC.
In the 2 × 104.0 TCID50 dose live-attenuated PCV1-2b
vaccine group, no pig had PCV2 genomic copy numbers
after challenge, except one pig that harbored 101.33
PCV2 genomic copy numbers at 14 DPC.
In the inactivated PCV1-2b vaccine group, no PCV2
genomic copy numbers were detected in the pigs after
challenge, except for one pig that had approximately
101.11 PCV2 genomic copy numbers at 21 DPC.
For the commercial inactivated PCV2b vaccine control
group, one out of four pigs had PCV2 genomic copy num-
bers that varied from 101.42 to 101.74 at 7 to 21 DPC.
Figure 3 shows a comparison of the PCV2 DNA load
in sera of the pigs challenged with PCV2. The PCV2 DNA
loads in serum were not significantly different among theFig. 3 Comparison of the PCV2 DNA loads in sera of the differently
treated pigs challenged with PCV2. The PCV2 genomic copy load
was presented as a log10 value of PCV2 genomic copy load per 1 ml
of sera. Different letters (A, B) indicate significant differences among
different groups at 7, 14, or 21 DPC (P < 0.05)vaccinated groups; however, the PCV2 DNA loads in non-
vaccinated challenged pigs were significantly higher than
those in the vaccinated groups (P < 0.05).
Detection of PCV2 DNA in superficial inguinal lymph nodes
At necropsy (DPC 21), PCV2 genomic DNA was de-
tected in the SILN in four of five pigs in group 1, in two
of five pigs in group 3, and in all pigs in groups 2, 4, and
5. The mean PCV2 viral genomic copies/g loads in ho-
mogenized SILN in samples that tested positive were
108.62 in group 1, 108.70 in group 2, 107.89 in group 3, 109.08
in group 4, and 1011.50 in group 5 (Fig. 4). The SILN viral
loads in pigs inoculated with the inactivated PCV1-2b
vaccine were slightly lower than those in pigs immunized
with live-attenuated or commercial inactivated PCV2b
vaccine, although the difference was not statistically
significant. Median PCV2 DNA copy loads in vaccinated
pigs were significantly lower than those in nonvaccinated
challenged pigs, in groups 1 and 5 (P = 0.0032), in groups
2 and 5 (P = 0.0019), in groups 3 and 5 (P = 0.0012), and in
groups 4 and 5 (P = 0.0154).Fig. 4 PCV2 DNA copies/g loads in SILN tissues collected on the day
of necropsy. PCV2 DNA was extracted from 50 μg of homogenized
SILN tissues and subjected to real-time PCR amplification. The PCV2
genomic copy loads are represented as a log10 value per 1 g of SILN
tissue (y axis) (*P < 0.05; **P < 0.01)
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No gross or microscopic lesions were observed in pigs
in the mock group (Fig. 5a, g). At necropsy, theFig. 5 Histopathological lesions in experimental conventional pigs. a No m
lymphoplasmacytic and histiocytic bronchointerstitial pneumonia in the lun
cMild lymphoplasmacytic and histiocytic bronchointerstitial pneumonia in the lung
and histiocytic bronchointerstitial pneumonia in the lung of a pig vaccina
lymphoplasmacytic and histiocytic bronchointerstitial pneumonia in the l
f Severe lymphoplasmacytic and histiocytic bronchointerstitial pneumonia in t
lesions in the lymph nodes of a pig in the mock group. h Slight lymphoid depl
dose attenuated PCV1-2b. i Mild LD in lymph nodes follicles of a pig vaccinated
vaccinated with 2×103.5 TCID50 dose attenuated PCV1-2b. k Conspicuous LD in
PCV2b vaccine X. l Moderate histiocytic replacement (HR) in lymph nodeenlargement of lymph nodes were observed in the vacci-
nated pigs and generally ranged from mild to moderate;
two pigs (two-times normal size) in the inactivatedarkable microscopic lesions in the lung of mock group pigs. b Slight
g of a pig vaccinated with 2×104.0 TCID50 dose attenuated PCV1-2b.
of a pig vaccinated with inactivated PCV1-2b. dModerate lymphoplasmacytic
ted with 2×103.5 TCID50 dose attenuated PCV1-2b. e Conspicuous
ung of a pig vaccinated with commercial inactivated PCV2b vaccine X.
he lung of a nonvaccinated challenged pig. g No remarkable microscopic
etion (LD) in lymph node follicles of a pig vaccinated with 2×104.0 TCID50
with inactivated PCV1-2b. j Moderate LD in lymph nodes follicles of a pig
lymph nodes follicles of a pig vaccinated with commercial inactivated
follicles of a nonvaccinated challenged pig. Bar = 20 μm (400×)
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dose live-attenuated vaccine group had mild enlarge-
ment, whereas two pigs (three-times normal size) in the
commercial inactivated PCV2b vaccine X group and one
pig in 2 × 103.5 TCID50 dose live-attenuated vaccine group
had moderate swelling. The lymph nodes of all five pigs
in the nonvaccinated challenged group were moderately
to severely enlarged.
In vaccinated pigs, two pigs in the commercial inactivated
PCV2b vaccine X group had lung lesions and only one pig
in the inactivated or live-attenuated PCV1-2b vaccine
group presented interstitial pneumonia; this was significant
differences (one or two pigs versus four pigs) compared
with nonvaccinated challenged pigs (Table 4, Fig. 5b-f).
Lymphoid depletion (LD) of lymph node follicles was
detected in one pig in the inactivated or live-attenuated
PCV1-2b vaccine groups and in two pigs in the commercial
inactivated PCV2b vaccine X group. Histiocytic replace-
ment (HR) of lymph node follicles was found in one pig in
the inactivated or 2 × 103.5 TCID50 dose live-attenuated
vaccine group, commercial inactivated PCV2b vaccine
X group, and in no pigs in the 2 × 104.0 TCID50 dose
live-attenuated vaccine group, compared with five pigs
that displayed LD and four of five pigs that displayed
HR in the nonvaccinated challenged group (Table 4,
Fig. 5h-l).
LD of the tonsil follicles was observed in one pig in
the inactivated or 2 × 103.5 TCID50 dose live-attenuated
vaccine group, commercial inactivated PCV2b vaccine X
group, and in no pigs in the 2 × 104.0 TCID50 dose live-
attenuated PCV1-2b vaccine group, whereas LD or HR
was detected in the tonsil follicles of three pigs in the
nonvaccinated challenged group.
LD of the spleen follicles was found in one pig in the
2 × 103.5 TCID50 dose live-attenuated PCV1-2b vaccine
group, commercial inactivated PCV2b vaccine X group,
and in no pigs in the inactivated or 2 × 104.0 TCID50
dose live-attenuated vaccine group, but three of five pigs
exhibited LD and two of five pigs exhibited HR effects.
In general, the characteristic LD and HR effects
were lower in vaccinated pigs compared with theTable 4 Distribution of histopathological lesions in different tissues
Group No. of pigs with lesions/no. examined
Lymph node Tonsil Spleen
LD HR LD HR LD HR
1 1/5 1/5 1/5 0/5 1/5 0/5
2 1/5 0/5 0/5 0/5 0/5 0/5
3 1/5 1/5 1/5 0/5 0/5 0/5
4 2/4 1/4 1/4 0/4 1/4 0/4
5 5/5 4/5 3/5 3/5 3/5 2/5
6 0/2 0/2 0/2 0/2 0/2 0/2
HR histiocytic replacement, LD lymphoid depletionnonvaccinated challenged pigs. Results regarding the
presence of lesions in all tissues and organs tested are
summarized in Table 4.
Amount of PCV2 antigen
At necropsy, the incidence and amount of PCV2 antigen
were reduced in vaccinated pigs compared with nonvac-
cinated challenged group pigs. PCV2 antigen was not de-
tected in the lymph node tissues of mock group (Table 5,
Fig. 6a) and there were very small amounts of PCV2
antigen in pigs vaccinated with 2 × 104.0 TCID50 dose live-
attenuated PCV1-2b (Fig. 6b). Low amounts of PCV2 anti-
gen were detected in one pig in the inactivated PCV1-2b
vaccine group (Table 5 Fig. 6c) Small amounts were found
in one pig in the 2 × 103.5 TCID50 dose live-attenuated
PCV1-2b vaccine group (Table 5, Fig. 6d). A moderate
amount was found in one pig in the commercial inactivated
PCV2b X vaccine group (Table 5, Fig. 6e). High amounts of
PCV2 antigen were detected in the lymph nodes of all non-
vaccinated challenged pigs (Table 5, Fig. 6f). No PCV2 anti-
gen was detected in the tonsil, spleen, and thymus of any
vaccinated pigs. However, varying amounts of PCV2
antigen were detectable in tonsils of two pigs and in spleen
and thymus of one pigs in the nonvaccinated challenged
group (Table 5).
Discussion
Currently, all commercially available PCV2 vaccines are
inactivated or subunit vaccines based on the PCV2a sub-
type [6, 20, 21]. It was demonstrated that the current
PCV2a subtype vaccines provide complete protection
against PCV2b challenge [26, 28]. Moreover, Opriessnig
et al. showed that the PCV1-2b vaccination significantly
reduced the prevalence and amount of PCV2b viremia
compared with the PCV1-2a vaccination [25]. Currently,
many swine producers and veterinarians prefer to use
single-dose administration because of decreased labor
costs. It has been reported that one-dose and two-dose
PCV2 vaccine products were equivalent in inducing
protective immunity, and the major disadvantage of not
giving a booster dose is the lack of generating a largerfrom experimental pigs challenged with PCV2
Lung Liver Kidney Heart Thymus Intestine
1/5 1/5 0/5 0/5 0/5 0/5
1/5 0/5 0/5 0/5 0/5 0/5
1/5 0/5 0/5 0/5 0/5 0/5
2/4 1/4 1/4 0/4 0/4 0/4
4/5 3/5 3/5 0/5 0/5 0/5
0/2 0/2 0/2 0/2 0/2 0/2
Table 5 Detection of PCV2 antigen in lymph node, tonsil,
spleen, and thymus of experimental pigs at 21 DPC
Group No. of pigs testing positive/no.tested
Lymph node Tonsil Spleen Thymus
1 1/5 0/5 0/5 0/5
2 0/5 0/5 0/5 0/5
3 1/5 0/5 0/5 0/5
4 1/4 0/4 0/4 0/4
5 5/5 2/5 1/5 1/5
6 0/2 0/2 0/2 0/2
DPC days post challenge
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after encountering with the antigen [22]. We have pre-
viously tested the efficacy of a two-dose inactivated
PCV1-2b vaccine using PCV2b challenge [29]. In this
study, we determined the efficacy of one-dose inactivated
or live-attenuated (2 × 103.5 or 2 × 104.0 TCID50 dose)
PCV1-2b vaccines in a wild-type PCV2b challenge model.
The optimal vaccination protocol of the inactivated
PCV1-2b vaccine was determined previously [30].Fig. 6 Immunohistochemical detection of PCV2 antigen in conventional pi
Very small amounts of PCV2 antigen in lymph nodes of a pig vaccinated with
antigen in nuclei of histiocytes and occasional lymphocytes of a pig vaccinate
of histiocytes and occasional lymphocytes of a pig vaccinated with 2×103.5 TC
nuclei of histiocytes and occasional lymphocytes of a pig vaccinated with com
nuclei of histiocytes and occasional lymphocytes of a nonvaccinated challengedExperimental pigs were vaccinated with 2 × 104.0, 2 ×
105.0 and 2 × 106.0 TCID50 of inactivated PCV1-2b virus.
The trial test results showed that vaccination with 2 ×
105.0 TCID50 of inactivated PCV1-2b virus was more ef-
fective for PCV2 challenge, and this was confirmed by
the data related to the level of antibodies against PCV2,
neutralizing antibodies, viral loads in serum or lymph
nodes and lesion in tissues. Corresponding to our previ-
ous study [29], all vaccines tested induced a high level
of neutralizing antibody in this study which may be an
important deterrent for virus replication [31].
In the current study, live-attenuated chimeric vaccine-
induced clinical signs were not observed and the average
daily weight gain was comparable with that of pigs in
the mock group, which confirmed that the live vaccine
was attenuated. All vaccinated pigs had seroconversion
to PCV2 by 21 DPV and peaked at 42 DPV in group 1
(average at 1:9600), at 35 DPV in group 2 (average at
1:13120), at 35 DPV in group 3 (average at 1:15680), and
at 28 DPV in group 4 (average at 1:5600) (Fig. 1). The
results indicated that pigs vaccinated with the inacti-
vated or live-attenuated vaccine developed high PCV2
antibody titers, which is consistent with a previouslygs. a No detection of PCV2 antigen in lymph nodes of mock pigs. b
2×104.0 TCID50 dose attenuated PCV1-2b. c Low amounts of PCV2
d with inactivated PCV1-2b. d Small amounts of PCV2 antigen in nuclei
ID50 dose attenuated PCV1-2b. e Moderate amounts of PCV2 antigen in
mercial inactivated PCV2b vaccine X. f High amounts of PCV2 antigen in
pig. Bar = 20 μm (400×). Hematoxylin-counterstained sections
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vaccine and inactivated vaccines [32, 33]. It needs to
be explained that only four pigs were present for the
duration of the study in the commercial inactivated
PCV2b vaccine X group, which was considered reasonable
for statistical analysis and should not have affected the
study outcome [32]. It is notable that the capsid protein is a
major viral structural protein, and molecular epidemiology
analyses have shown that the ORF2 gene is highly variable
compared with ORF1 and ORF3 in the PCV2 populations
[34, 35]. Therefore, a novel chimeric PCV1-2b with the
capsid gene of the PCV2b/1B/Jiangsu/Jingjiang/2012/11/08
cloned into the genomic backbone of PCV1 was generated;
the capsid gene shares 95.3 % nucleotide sequence identity
with the previous PCV1-2b-1C strain and the efficacy of
protective immunity was compared in the future.
As expected, vaccination reduced PCV2 genomic copy
number in serum, SILN samples and PCV2 antigen in
tissues sections compared with nonvaccinated challenged
pigs. PCV2 DNA levels peaked at 14 DPC and then de-
clined. Vaccination with the 2 × 104.0 TCID50 dose live-
attenuated PCV1-2b resulted in lower PCV2 genomic
copy numbers in serum than with the 2 × 103.5 TCID50
dose live-attenuated PCV1-2b, which directly correlated
to the higher IFA antibody titers in vaccinated pigs. These
data may indicate that the humoral immunity induced by
the vaccine interferes with PCV2 replication [33, 36]. Fur-
thermore, no PCV2 viremia was present in live-attenuated
PCV1-2b immunized pigs at 21 DPC, suggesting that live-
attenuated vaccines may induce better cellular immune
response, although the exact mechanism for the decrease
of PCV2 viremia in vaccinated pigs is unknown. Lymphoid
tissues are the main targets of PCV2 in pigs with related
diseases; PCV2 replication in lymph nodes results in
degradation of lymphoid structures and impairment of
the immune system [37–39]. The amount of PCV2
copy numbers in SILN is important to evaluate the vac-
cine efficacy. At 21 DPC, PCV2 genome was detected in
high amounts in SILN of nonvaccinated challenged pigs,
but low amounts in vaccinated pigs. The mean PCV2 copy
numbers of positive SILN samples were 8.62 ± 0.64, 8.70 ±
0.54, 7.89 ± 0.39, and 9.08 ± 0.77 in vaccinated groups, re-
spectively, compared with 11.5 ± 0.30 in the nonvacci-
nated challenged group, the difference was statistically
significant (P < 0.05). The distribution of PCV2 antigens
was described by IHC, PCV2 antigen was undetected in the
2 × 104.0 TCID50 dose live-attenuated vaccine group and
detected only in one pig in the inactivated or 2 × 103.5
TCID50 dose live-attenuated PCV1-2b vaccine group, and
the commercial inactivated PCV2b vaccine X group was
positive for PCV2 antigen in lymphoid tissues. In contrast,
all pigs tested were positive in the nonvaccinated challenged
group. These findings are in agreement with a previous study
[29] and imply that inactivated and live-attenuated PCV1-2bvaccines can significantly reduce the amount of PCV2
virus in serum or lymphoid tissues, which are characteris-
tic factors in the pathogenesis of PCVAD in pigs [40, 41].
In this study, the observed PCV2-associated microscopic
lesions were milder in the lung and lymphoid tissues in all
vaccinated pigs compared with the nonvaccinated challenged
pigs. In addition, the clinical signs of disease were not
observed in the vaccinated pigs. We found that in non-
vaccinated challenged pigs, LD and HR of follicles were as-
sociated with high PCV2 viral copy numbers and more
serious histological lesions in lymph node, spleen, and tonsil
which may eventually progress to clinical PMWS [37, 42]. In
contrast, vaccinated pigs with high antibody titers presented
mild microscopic lesions and PCV2 viremia after challenge.
Conclusions
In summary, the data from this study demonstrate that
pigs vaccinated with inactivated or live-attenuated chimeric
PCV1-2b vaccines were equally protected against PCV2
challenge, as evidenced by the lack of PCV2 viremia,
significant reduction in viral loads in lymphoid tissues
and significantly less lymphoid lesions in vaccinated
pigs. This chimeric PCV1-2b virus may be a good candidate
not only as an inactivated vaccine but also as a live-
attenuated vaccine against PCV2 infection.
Materials and methods
Cells and viruses
PCV-free PK-15 cells used in this study were purchased
from the China Institute of Veterinary Drug Control and
grown in Dulbecco’s modified Eagle’s medium (DMEM;
Sigma), supplemented with 4 % fetal bovine serum (FBS;
Gemini). The construction of the recombinant pBSK(+)-
dPCV1-2b plasmid was reported previously [29]. PCV2b/
1B/Jiangsu/Jingjiang/2012/11/08 isolated from a pig with
clinical manifestation of PMWS was sequenced for the en-
tire viral genome (GenBank accession no. KJ599673).
Vaccine preparation
Chimeric PCV1-2b live viruses were generated by elec-
troporation of PK-15 cells as previously reported [43].
Briefly, the trypsinized PK-15 cells were transferred to a
sterile electroporation microcuvette containing 6 μg of
plasmid DNA resuspended in 400 μL of transfection
buffer. The electroporation parameters were three 400-
μs pulses at 250 V. After electroporation, fresh DMEM
containing 4 % FBS was added and transferred to six-
well plates, which were incubated at 37 °C with 5 % CO2
for 48 h. Cells were then harvested.
To determine the infectivity titers of the chimeric
PCV1-2b viruses, PK-15 cells were cultivated on 96-well
plates, and then the cells were infected with a 10-fold serial
dilutions of PCV1-2b. After 72 h of incubation, the virus ti-
ters were determined by an indirect immunofluorescence
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with methanol and then incubated with PCV2 anti-
serum (1:1000 dilution; VMRD). After washing three
times with phosphate-buffered saline (PBS; 0.01 M,
pH 7.2), the cells were incubated with fluorescein isothiocyan-
ate (FITC)-labeled rabbit anti-pig IgG (Southern Biotech).
Virus titers were determined using a fluorescence micro-
scope (IX51; Olympus).
Then, the chimeric PCV1-2b viruses were diluted to
103.5 TCID50/ml and 10
4.0 TCID50/ml and were regarded
as live-attenuated PCV1-2b vaccines. The inactivated
chimeric PCV1-2b vaccine was developed using the fol-
lowing steps. Briefly, live chimeric viruses with a titer of
105.5 TCID50/ml were incubated with formalin at a final
concentration of 0.1 %, kept at 4 °C for 12 h, and spun at
120 rpm at 37 °C for 12 h. Virus inactivation was confirmed
by the inoculation of the formalin-treated samples into PK-
15 cells and serially passaged for two generations, and then
tested by IFA. Next, the inactivated PCV1-2b viruses were
mixed with ISA 206 adjuvant (Seppic, Paris, France) at a ra-
tio of 46:54 (V/V), and the inactivated chimeric PCV1-2b
viruses in the prepared vaccine reached 105.0 TCID50/ml.
Experimental design
The experimental protocol was previously approved by the
Animal Care and Use Committee of Yangzhou University
(approval ID: SYXK [Su] 2005–0005). Twenty-seven 3-
week-old conventional pigs were randomly divided into six
groups, including four vaccination groups and two control
groups (Table 1). All pigs were negative for PCV2, porcine
reproductive and respiratory syndrome (PRRSV), porcine
parvovirus (PPV), porcine pseudorabies virus (PRV), and
classic swine fever virus (CSFV) according to IFA and poly-
merase chain reaction (PCR) tests. Each group of pigs was
housed separately. The pigs in groups 1 to 4 were vacci-
nated in the right side of the neck at 3 week old. Live-
attenuated PCV1-2b was given as 2 ml × 103.5 TCID50 and
as 2 ml × 104.0 TCID50 (groups 1 and 2), respectively; inacti-
vated PCV1-2b vaccine was given as 2 ml × 105.0 TCID50
(group 3). A commercial inactivated PCV2b vaccine named
X, which is available on Chinese market, was given as a 2.0-
ml dose as recommended by the manufacturer (group 4).
Phosphate-buffered saline (PBS; 0.01 M, pH 7.2) was given
as a 2.0-ml dose (groups 5 and 6). At 28 days post vaccin-
ation (DPV), pigs in all groups, except for the mock group,
were challenged with 2 ml of wild-type PCV2b/1B/Jiangsu/
Jingjiang/2012/11/08 at a titer of 104.8 TCID50/ml. After
challenge, all pigs were monitored daily for clinical signs of
diseases. Blood samples were collected at −1, 7, 14, 21, and
28 DPV and at 7, 14, and 21 DPC until necropsy.
Clinical evaluation
Pigs were weighed at 0 DPV and weekly thereafter until
the day of necropsy. Rectal temperatures and clinicalobservations, including evidence of central nervous
system disease, icterus, musculoskeletal disease, and
changes in body condition, were recorded daily [20].
Titer of anti-PCV2 IgG antibodies and neutralizing
antibodies
The serum samples were tested for the presence of PCV2
antibodies by IFA [21]. Briefly, 200 TCID50 PCV2 virus was
added to PK-15 cells that were grown in 96-well plates.
After 72 h incubation, the infected cells were fixed with
methanol for 15 min and then incubated with the serum
specimen diluted in PBS at 1:10, 1:100, 1:200, 1:400, 1:800,
1:1600, 1:3200, 1:6400, 1:12,800, and 1:25,600. After incuba-
tion at 37 °C for 1 h, the cells were washed with PBS and
incubated with FITC-labeled rabbit anti-pig immunoglobu-
lin G (Southern Biotech) at 37 °C for 45 min. The antibody
titer was defined as the highest dilution time of serum
under a fluorescence microscope (IX51; Olympus).
The titer of neutralizing antibody (NA) against PCV2 was
assessed according to the fluorescence focus neutralization
(FFN) assay [29, 44, 45], with minor modifications. Briefly,
the tested serum samples were inactivated at 56 °C for
30 min, serially diluted two-fold (1:2 to 1:128), mixed with
200 TCID50 PCV2 virus at an equal volume ratio and incu-
bated for 1 h at 37 °C. The serum-virus mixture was added
to confluent PK-15 cells growing in 96-well plates. After
incubation at 37 °C for 72 h, a similar IFA protocol was
performed. Serum NA titer was determined as the highest
dilution at which there was 90 % or greater reduction in
virus replication compared with the virus control.
Quantification of PCV2 DNA in blood and superficial
inguinal lymph nodes
All serum samples at 7, 14, and 21 DPC and superficial
inguinal lymph nodes (SILN) were tested for amount of
PCV2 DNA. A pair of primers (5′-TGGCCCGCAGTATT
CTGATT-3′ and 5′-CAGCTGGGACAGCAGTTGAG-
3′), and a probe (5′-6FAM-CCAGCAATCAGACCCCGT
TGGAATG-TAMRA-3′) were designed to target a highly
conserved region in PCV2 ORF1 according to a previously
reported method [24]. Viral DNA was extracted from
100 μl of serum samples and 50 μg of SILN tissue; resulting
DNA was suspended in 100 μl of sterile water [20]. The
quantitative real-time PCR assays were performed on a
Roche Real-Time PCR Detection System (LightCycler®
Nano, Roche, Basel, Switzerland) using a Roche Fas-
tStart Essential DNA Probes Master Kit (Roche). Samples
were considered negative when no signal was observed
during the 40 amplification cycles. All reactions were per-
formed in triplicate.
Histopathology
All pigs underwent necropsy and were evaluated by vet-
erinary pathologists in a blinded fashion at 21 DPC.
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liver, spleen, small intestine, colon, kidney, and lymph
nodes (tracheobronchial, mediastinal, mesenteric, subiliac,
and superficial inguinal) were collected, fixed in 10 %
neutral buffered formalin, and routinely processed for
histological examination.
Immunohistochemistry
Immunohistochemistry (IHC) for detection of PCV2-
specific antigen was performed on selected formalin-fixed
and paraffin-embedded sections of lymph nodes, tonsil,
spleen, and thymus tissues using a pig polyclonal anti-
serum (VMRD) [46]. The amount of PCV2 antigen dis-
tributed was scored by veterinary pathologists in a blinded
fashion. Scores ranged from 0 for no signal to 3 for more
than 50 % with PCV2 antigen staining [47].
Statistical analysis
Statistical analysis was performed using SPSS software
(version 13.0). Viral copy loads in serum samples or SILN
tissue were transformed to values of log10 viral copy with
Graphpad Prism v5.0 software package (Graphpad Soft-
ware, La Jolla, CA) and expressed as means with standard
deviations. The t tests (and nonparametric tests) were
used to draw the graphs to display PCV2 viral copy loads
in serum samples or SILN tissue and the dynamics of
seroconversion to PCV2-specific IFA antibody.
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